Skip to main content

Hilleman Labs’ provide preclinical trial report on Hib vaccine

 

Clinical courses

Hilleman Laboratories is a first-of-its-kind joint-venture partnership formed between Merck & Co., a global research-driven pharmaceutical organization and Wellcome Trust, a global charitable foundation dedicated to human and animal health by supporting the brightest minds. Hilleman Laboratories (HL)  claimed to have made a break-through research  on the success of a preclinical trial conducted for Haemophilus influenza type b (Hib) vaccine offering hope to millions of children and needy people. Hilleman Laboratories announced the publication of an original scientific report in the journal 'Vaccine' based on the success of a pre-clinical trial conducted for the vaccine.

Hib is a deadly bacterium that causes severe diseases like pneumonia and meningitis, which are the leading causes of child deaths in India, accounting for nearly 20% of the global death figures. Hib capsular polysaccharides (Hib-PRP) are poorly immunogenic in children less than two years of age and require conjugation to a protein carrier.

The Hib conjugate vaccine, which plays a vital role in national immunization programmes and also forms a main part of the pentavalent vaccine. The new conjugate vaccine developed by Hilleman Laboratories is a more immunogenic preparation of Hib capsular polysaccharide (PRP) – tetanus toxoid (TT) conjugates using optimized PRP chain length and conjugation conditions.

This new and unique cost-effective formulation developed by the company will significantly reduce the cost of Hib vaccine, which in turn, will help in reducing the market price of the pentavalent vaccine, thus making it accessible to a larger number of people. This will definitely have a larger economic impact on the public health system and subsequently bring down the expenditure in the system.


<< Pharma News

Subscribe to PharmaTutor News Alerts by Email >>